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Abstract 
Background: Human T cell lymphotropic virus type 1 (HTLV-1) is the etiological agent of a severe form of neoplasia 
designated Adult T cell Leukaemia (ATL). It is widely accepted that the viral transactivator Tax-1 is the major viral prod-
uct involved in the onset, but not in the maintenance, of neoplastic phenotype, as only 30–40% of ATL cells express 
Tax-1. It has been recently demonstrated that HBZ (HTLV-1 bZIP factor), a protein encoded by the minus strand of 
HTLV-1 genome, constantly expressed in infected cells and in ATL tumor cells, is also involved in the pathogenesis of 
leukaemia. The full role played by HBZ in oncogenesis is not clarified in detail also because of the limited availability of 
tools to assess quantitative expression, subcellular location and interaction of HBZ with host factors in ATL.
Results: By the use of the first reported monoclonal antibody against HBZ, 4D4-F3, generated in our laboratory it has 
been possible to carefully assess for the first time the above parameters in HTLV-1 chronically infected cells and, most 
importantly, in fresh leukemic cells from patients. Endogenous HBZ is expressed in speckle-like structures localized in 
the nucleus. The calculated number of endogenous HBZ molecules varies between 17.461 and 39.615 molecules per 
cell, 20- to 50-fold less than the amount expressed in HBZ transfected cells used by most investigators to assess the 
expression, function and subcellular localization of the viral protein. HBZ interacts in vivo with p300 and JunD and co-
localizes only partially, and depending on the amount of expressed HBZ, not only with p300 and JunD but also with 
CBP and CREB2.
Conclusions: The possibility to study endogenous HBZ in detail may significantly contribute to a better delineation 
of the role of HBZ during HTLV-1 infection and cellular transformation.
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Background
HTLV-1 is an oncogenic retrovirus responsible of 
a severe form of cancer, the Adult T cell Leukemia 
(ATL), characterized by the malignant transforma-
tion of CD4+ T cells [1]. HTLV-1 also causes a severe 
neurological disorder designated HTLV-1-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP) 
[2]. Ten million people are infected worldwide although 
this number is certainly underestimated [3]. Like other 
retroviruses HTLV-1 produces structural proteins, Gag, 
Pol and Env, encoded by the plus strand of the viral 
genome (reviewed in [4]). The HTLV-1 genome expres-
sion is mainly influenced by two regulatory proteins, 
Tax-1 and Rex, encoded by the 3′ region of viral genome 
between env and 3′ LTR [4]. The viral protein Tax-1 is 
important for the transcription of the provirus and its 
oncogenic potential [5]. The minus strand of the viral 
genome encodes a transcript [6] whose protein product 
is designated HTLV-1 bZIP factor (HBZ) [7]. Interest-
ingly, while Tax-1 is expressed only in 40% of cells from 
ATL patients, HBZ transcripts are constantly found in 
all ATL cells [4, 8]. This probably reflects the fact that 
HBZ is also important for infectivity and persistence 
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in  vivo [9]. HBZ contains a bZIP domain in addition 
to an activation (N-terminus) and a central domain 
[7]. There are two different isoforms of this protein: 
a spliced form containing 206 amino acids (sp1) and 
an unspliced form with 209 amino acids (us) [10, 11]. 
The sp1 form is more abundant and is found in almost 
all ATL patients [8]. Spliced HBZ is more potent than 
unspliced HBZ in inhibiting transcription from viral 
5′ LTR. Indeed, experiments using cells transfected 
with tagged HBZ have shown that HBZ interacts with 
CREB-2 via its bZIP domain resulting in strong inhibi-
tion of the CREB-2/Tax-1 interaction instrumental for 
the activation of HTLV-1 LTR [7]. In addition to inter-
acting with CREB-2, similar experiments have shown 
that HBZ binds to different proteins of the JUN family 
via its bZIP domain [12]. The binding to JunB and cJun 
induces a sequestration of these factors in nuclear bod-
ies or an accelerated degradation of them. As a result, 
HBZ reduces the cJun/JunB-mediated transcriptional 
activation of a series of genes. Conversely, the bind-
ing of HBZ to JunD does not inhibit the JunD-mediated 
transcriptional activation of target genes; indeed HBZ-
JunD complex upregulates even the expression of HBZ 
encoding gene [13, 14]. Interestingly, in many cases HBZ 
exerts opposite effects with respect to Tax-1 on signal-
ing pathways (reviewed in [15]). HBZ interacts with the 
KIX domain of p300/CBP to deregulate their interaction 
with cellular factors. This interaction strongly affects 
also the Tax-1-dependent, p300/CBP-mediated viral 
transactivation [16]. HBZ inhibits, while Tax-1 activates, 
the classical Nuclear Factor kappa B (NFkB) pathway by 
inducing PDLIM2 expression which brings about pro-
teasomal degradation of RelA [17]. HBZ suppresses, 
while Tax-1 activates, Wnt pathway by interacting with 
the disheveled-associating protein with a high frequency 
of Leucine residues (DAPLE) [18]. HBZ inhibits produc-
tion of Th1 cytokines (particularly IFN-γ) by interacting 
with NFAT and thus impairing cell-mediated immunity 
[19]. A number of effects suggest an important action of 
HBZ in supporting and/or maintaining the proliferation 
of HTLV-1 infected cells and by this the initiation and 
persistence of ATL. For example, the interaction of HBZ 
with JunD activates the telomerase by up-regulating the 
expression of hTERT [20]. HBZ interacts with ATF3 
and reduces the interaction of ATF3 with p53, possibly 
interfering with p53 signaling leading to apoptosis and 
thus increasing the potential of ATL cells to proliferate 
[21]. HBZ interacts with Smad3 and C/EBPα in a ternary 
complex which suppresses C/EBPα signaling pathway, 
again favoring proliferation of ATL cells [22]. Moreo-
ver, the capacity of HBZ to participate in ternary com-
plexes with Smad3 and its interacting factors, such as 
p300, may explain the up-regulation of TGFβ signaling 
pathway that is activated by Smad3-p300. Interestingly 
TGFβ may increase the expression of FoxP3, a marker 
of regulatory T cells (Tregs) which can be infected by 
HTLV-1 [23]; this may predispose to the onset of ATL 
since the CD4+Foxp3+ Treg cell phenotype has been 
found in ATL leukemic cells [24, 25] although this aspect 
is still controversial [26].
Most of the reported sub-cellular localizations, bio-
chemical interactions with cellular components and 
functional aspects related to HBZ have been assessed on 
cells transfected with HBZ in which the protein is usu-
ally overexpressed. The lack of suitable reagents such as 
monoclonal antibodies against the native, endogenous 
HBZ has not permitted to corroborate and validate all 
the functions attributed to HBZ, particularly in natu-
rally HTLV-1 infected cells and in tumor cells of ATL 
patients. Here we began to fill-up this gap by generating 
a monoclonal antibody that can specifically react with 
endogenous HBZ in HTLV-1 infected and in ATL tumor 
cells. This has allowed a more precise definition of the 
subcellular localization of HBZ, its interaction with cel-
lular factors and an estimate of its amount in vivo both in 
HTLV-1 infected and in ATL tumor cells.
Results
4D4‑F3, the first reported monoclonal antibody specifically 
recognizing HBZ protein
Spleen cells of a mouse immunized with GST-tagged HBZ 
were fused with myeloma cells (P3U1) using PEG (poly-
ethylene glycol). The resulting hybridomas were selected in 
a HAT medium and their supernatants screened by west-
ern blot against the immunizing antigen. Out of the 96 
hybridomas screened, one designated 4D4 showed strong 
positivity. The specificity for HBZ was demonstrated by 
its reactivity for a differently tagged HBZ protein (myc-
HBZ) (Additional file  1: Figure S1). The 4D4 hybridoma 
cells were cloned by limiting dilution and supernatants 
from single clones were screened by ELISA. Among vari-
ous positive clones, we further selected the 4D4-F3 clone 
for its strong reactivity also in western blotting analysis 
(Additional file  1: Figure S1). 4D4-F3 monoclonal anti-
body (mAb) was isotyped as IgG1 with kappa light chain 
by ELISA.
In order to delineate the HBZ epitope region recog-
nized by 4D4-F3, an epitope mapping was carried out. 
For this purpose lysates of Cos cells transfected with 
either Green Fluorescent Protein (GFP)-tagged HBZ or 
a series of GFP-HBZ deletion mutants were analyzed 
by western blot. 4D4-F3 mAb recognized all fragments 
including the basic region 1 (BR1) fragment of HBZ, the 
isolated diagnostic BR1 fragment but not the isolated 
DBD fragment (Figure  1a, left panel). The presence of 
the DBD fragment in the corresponding lysate and its 
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immunogenicity was confirmed by the reactivity of the 
serum of the mouse whose spleen cells were used for 
fusion (Figure 1a, right panel). Based on the above results 
the epitope recognized by 4D4-F3 mAb was mapped 
to the region between amino acids 97–133 (Figure  1b) 
including the BR1 region. Figure  1b summarizes the 
results of epitope mapping, listing all the different HBZ 
deletion mutants used and their size.
Subcellular localization of HBZ as assessed by the 4D4‑F3 
monoclonal antibody
4D4-F3 mAb was used to assess the localization and the 
distribution of HBZ, first in transfected cells and then 
in HTLV-1 infected and in ATL tumor cell lines. Previ-
ous studies using GFP-tagged HBZ or myc-tagged HBZ 
constructs transfected in COS or 293T cells, have docu-
mented a nuclear localization of HBZ in characteristic 
nuclear speckles [7, 12]. In our hands, GFP-HBZ trans-
fected in 293T cells also showed a distribution in nuclear 
speckles (Figure  2a1). When the same cells were incu-
bated with the 4D4-F3 mAb, a very intense staining was 
observed in the speckle-like nuclear structures virtually 
overlapping with the GFP-HBZ staining (Figure 2a2, a3, 
respectively). Interestingly, however, when GFP-HBZ 
deletion mutants were analyzed, a more refined and 
selective staining by the 4D4-F3 antibody was observed. 
This was particularly evident for the GFP-∆ZIP and 
GFP-∆AD nuclear fragments that often displayed strong 
green fluorescence staining in large nuclear aggregates. 
These structures were not observed with 4D4-F3 that 
instead detected HBZ in speckle-like structures (Figure 2, 
compare b2 and c2 with b1 and c1, respectively). This 
result strongly suggests that the GFP-related aggregates 
do not reflect a true HBZ nuclear distribution, possibly 
representing an artifact due to GFP. Virtual overlap in the 
staining between GFP and 4D4-F3 antibody was instead 
found for the predominantly cytoplasmic BR1 and the 
predominantly nuclear BR1-BR2-DBD HBZ fragments 
(Figure 3d1, d2 and f1, f2, respectively). Importantly, the 
4D4-F3 antibody did not stain the GFP-DBD fragment 
(Figure 3e2) further confirming the results of the epitope 
mapping.
Pattern of expression of endogenous HBZ protein 
in HTLV‑1 infected and in ATL tumor cells
It was then investigated the crucial aspect of detec-
tion and cellular distribution of endogenously made 
HBZ in HTLV-1 infected cells and in ATL tumor cells. 
To this purpose, three cell types were used: the HTLV-1 
chronically infected C5MJ cell line, the ATL-2s cell line 
Figure 1 Epitope assignment of 4D4-F3 anti-HBZ mAb. a Western blot analysis of full length GFP-tagged HBZ (HBZ) and a series of GFP-tagged 
HBZ fragments listed in the top of the left and right panels. Cos cells were transfected with the various encoding GFP-HBZ cDNAs, with empty 
plasmid (mock) or with GFP cDNA (GFP). Twenty-four hours after transfection cell lysates were prepared and analyzed by western blotting using the 
4D4-F3 anti HBZ mAb (left panel) or the anti-HBZ antiserum prepared from the same animal used for somatic cell fusion (right panel). b Schematic 
representation of the same results depicted in a. The various HBZ constructs are listed on the left side followed by bars representing size and regions 
of the specific fragment analyzed. Numbers indicate the specific aminoacid position in the various fragments. Plus (+) and minus (−) symbols indi-
cate positive or negative reactivity, respectively, of the 4D4-F3 mAb. AD activation domain, BR1 basic region 1, BR2 basic region 2, DBD DNA binding 
domain, bZIB b zipper domain.
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derived from a patient with Adult T cell leukemia, and 
importantly, one fresh sample of peripheral blood mon-
onuclear cells (PBMC) from a patient suffering of acute 
ATL. Preliminary analysis of the cell surface phenotype 
of C5MJ, ATL-2s and patient PH961 cells showed that 
C5MJ expresses CD4 and CD25 but not CD3, while ATL-
2s did not express appreciable amounts of any of these 
markers. On the other hand, PBMC of the ATL patient 
PH961 expressed CD3 and CD25 in 100% of the cells and 
CD4 in 26% of the cells (Additional file 2: Figure S2). This 
rather diversified pattern of expression of T cell markers 
in HTLV-1 infected and in ATL cells has been previously 
observed by other investigators [27, 28]. Results of the 
confocal microscopy analysis are shown in Figure  3. In 
the two cell lines and in PBMC from ATL patient PH961, 
HBZ was detected in the characteristic speckle-like dis-
tribution in the nucleus, although the number of nuclear 
speckles was clearly lower as compared to that found in 
293T cells transfected with untagged HBZ. No specific 
stain in the cytoplasm was detected. In addition, no sig-
nal was detected by the 4D4-F3 mAb in HBZ-negative 
Jurkat T cells, supporting the specificity of the mono-
clonal antibody. The speckle-like distribution of HBZ is 
reminiscent of a similar distribution of promyelocytic 
leukaemia protein (PML) nuclear bodies (PML-NB). 
PML is important in HTLV-1 infection because it may act 
as coactivator for the HTLV-1 Tax oncoprotein, although 
without direct binding [29]. Thus we assessed whether 
HBZ co-localizes with PML-NB. Results show that HBZ 
nuclear speckles and PML-NB do not overlap (Additional 
file 3: Figure S3), thus indicating that HBZ does not co-
localize with PML-NB.
Careful analysis of confocal images allowed estimat-
ing the average number of HBZ-positive cells in PBMC 
of ATL patient and in the two cell lines, in comparison 
with the average HBZ-positive cells detected in HBZ-
transfected 293T cells. ATL-2s cells were all positive 
for HBZ expression. Similarly, at least 80% of the ATL 
patient PBMC stained positive with the anti-HBZ mAb 
although with variable intensity. Seventy-five percent of 
the C5MJ cells stained positive for HBZ. In the reported 
experiment, 55% of HBZ-transfected 293T cells stained 
positive for HBZ.
Quantification of endogenous HBZ protein in HTLV‑1 
infected and in ATL tumor cells
We further investigated whether the 4D4-F3 antibody 
could be used to estimate the amount of HBZ protein 
present in HTLV-1 infected and in ATL tumor cell lines. 
To this purpose, increasing amounts of purified GST-
tagged HBZ protein were used to construct a standard 
curve by western blotting with the 4D4-F3 antibody; 
Figure 2 Subcellular localization of full length HBZ and HBZ fragments as assessed by the 4D4-F3 mAb. Full length GFP-tagged HBZ (HBZ) and a 
series of GFP-tagged HBZ fragments listed in the top of the figure, were transfected into 293T cells and their subcellular localization investigated by 
confocal microscopy either as GFP fluorescence (first series of horizontal panels, a1–f1) or as reactivity with the 4D4-F3 mAb followed by Alexa fluor 
546-labeled goat anti-mouse antibody (second series of horizontal panels, a2–f2). Third series of horizontal panels represent the merge between the 
GFP and the Alexa fluor 546 signals (a3–f3).
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specific bands were then quantified by densitometry. As 
little as two ng of HBZ protein could be clearly detected 
by this approach (Figure 4a). Subsequently we performed 
western blot analysis of cell lysates from a fixed number 
of 293T cells transfected with the standardized dose of 
3 μg of untagged HBZ DNA (Figure 4b) and plot the cor-
responding densitometry data on the curve constructed 
with the GST-tagged HBZ. This allowed defining a 
Figure 3 Subcellular localization of endogenous HBZ in HTLV-1 chronically infected and in ATL tumor cells. C5MJ and ATL-2s cell lines and PH961 
patient PMBC were stained with the 4D4-F3 antibody, followed by Alexa fluor 546-labeled goat anti-mouse antibody and analyzed by confocal 
microscopy. 293T cells transiently transfected with myc-HBZ cDNA plasmid and the human T cell line Jurkat were used as positive and negative 
controls, respectively. Right panels show a representative single cell of each corresponding field. The percentage of HBZ-positive cells was calculated 
by counting at least 200 cells. Results were ATL-2s, 100%; C5MJ, 75%; PH961, 80%; 293T.HBZ, 55%.
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provisional value of the amount of HBZ present in the 
transfected cells on a per-cell basis. This value was cal-
culated by taking into account the average percentage 
of HBZ transfected cells as shown in Figure  3, and it 
was found to be 20.36 ×  10−2 pg/cell, corresponding to 
783.000 molecules/cell. Similar experiments were per-
formed with cell lysates of C5MJ and ATL-2s cell lines, 
as well as PH961 patient cells (Figure  4a). It must be 
stressed that in order to visualize by western blot specific 
HBZ bands in C5MJ, ATL-2s and in the PH961 patient 
cell lysates, comparable for intensity with HBZ-trans-
fected 293T cells, it was necessary to process 10 times 
more cells. Assuming a molecular weight of 26  kDa for 
endogenous HBZ, after appropriate comparison by plot-
ting densitometry values on the standard curve it was 
estimated that HBZ-positive C5MJ or ATL-2s cell lines 
contained an average of 0.65 × 10−2 pg/cell correspond-
ing to 33.385 molecules/cell, and 1.03  ×  10−2  pg/cell 
corresponding to 39.615 molecules/cell, respectively. 
For patients PH961 cells it was estimated an average of 
0.45 × 10−2 pg/cell corresponding to 17.461 molecules/
cell (Figure  4c). Therefore, with all the limitation of the 
analysis used, we could conclude that the amount of the 
endogenously made HBZ molecules in freshly isolated 
ATL cells, in ATL cell line and in a chronically infected 
cell line was comparatively much lower (20- to 50-fold 
lower) than the one observed in transiently transfected 
293T cells.
Endogenous HBZ interacts with several nuclear factors 
but co‑localizes only partially with them
The 4D4-F3 anti-HBZ mAb was then used to assess the 
possible biochemical interactions and subcellular co-
localizations of HBZ with cellular factors in the above-
described ATL tumor cells and HTLV-1 chronically 
infected cells. Many nuclear factors have been reported 
to interact with HBZ. However, as pointed out earlier, 
most of these interactions were assessed in 293T or Cos 
cells transfected with tagged HBZ, in conditions of HBZ 
overexpression and in non- physiological cellular mod-
els of HBZ expression. We first checked the existence of 
in vivo interaction between HBZ and two crucial nuclear 
factors such as JunD and CBP that are involved in sev-
eral steps of both HTLV-1 replication and regulation 
of the cellular gene expression. Cell extracts of C5MJ, 
ATL-2s and, importantly, of patient PH961 were first 
immunoprecipitated with the 4D4-F3 anti-HBZ mAb, 
and the resulting immunoprecipitate run in SDS-PAGE, 
blotted on filter and reacted with antibodies specific for 
either JunD or CBP. Results clearly indicate that endog-
enous HBZ interacts with both JunD and CBP (Figure 5), 
although to different extent depending on the cell ana-
lyzed and the amount of HBZ expressed. Indeed, both 
CBP and JunD interaction with HBZ were better detected 
in C5MJ and ATL-2s than in PH961 cells, and this cor-
related with the higher amount of HBZ expressed in the 
first two cells compared to the patient ATL tumor cells. 
As expected, over-expression of HBZ in 293T cells trans-
fected with the viral gene was accompanied by a quanti-
tatively higher interaction with both CBP and JunD, again 
suggesting that the limiting factor for biological interac-
tion was the concentration of HBZ expressed by the cell.
To further extend the study on the subcellular location 
of possible interaction between HBZ and cellular factors 
in HTLV-1 infected and ATL tumor cells, an extensive 
analysis by confocal microscopy was carried out. More-
over, confocal investigation was extended, besides CBP 
and JunD, also to p300 and CREB-2, as well as nucleolin 
a marker of nucleoli. Importantly, CREB-2 was one of the 
Figure 4 Quantification of endogenous HBZ expression in HTLV-1 
chronically infected and in ATL tumor cells. a Three serial dilutions of 
purified GST-tagged HBZ protein (HBZ.GST) in nanograms (ng) were 
prepared in lysis buffer, run in SDS-PAGE gel, blotted in nitrocellulose 
filter, and filter reacted with the 4D4-F3 anti-HBZ mAb. Similarly, 
40 μl of 1 ml cell lysates from C5MJ, ATL-2s, PH961 patient ATL tumor 
cells [PH961(a) and PH96(b)], two distinct cell lysates of equivalent 
number of cells, 293T cells transfected with HBZ-myc (293T.HBZ) and 
Jurkat cells, were run in the same gel and processed as above. Cell 
lysates were from the same cells analyzed by confocal microscopy 
and shown in Figure 1. It must be underlined that in order to obtain 
comparable western blots, C5MJ, ATL-2s and PH961 patient cell 
lysates were prepared from 10 times more cells as compared to 293T.
HBZ cell lysates; this corresponded to 330.000 cells for the first three 
cell lysates vs 33.000 cells for 293T.HBZ cell lysate. Jurkat cell lysate 
was from 35.000 cells. b The expression of endogenous α-tubulin, 
used as internal control of sample loading. In this case, lysates from 
equal number of cells of the various samples were loaded in the gel. 
c The calculated amounts of HBZ in picograms/cell and in number of 
molecules/cell for the distinct cell sample are listed.
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first identified cellular nuclear proteins interacting with 
HBZ via its bZIP domain and this interaction was shown 
to inhibit the CREB-2/Tax-1 interaction instrumental for 
the activation of HTLV-1 LTR and the subsequent viral 
replication. The results of such analysis are shown in Fig-
ure  6 for C5MJ, in Figure  7 for ATL-2s and in Figure  8 
for patient PH961. In all figures, the first series of vertical 
panels depicts the distribution of HBZ protein (in red flu-
orescence), the second series of vertical panels the stain-
ing pattern of the various nuclear markers listed in each 
panel (in green fluorescence) and in the third series of 
vertical panels the merged fluorescence. The fourth series 
of vertical panels depicts the peak fluorescence distribu-
tion along a single line section (ROI) of the correspond-
ing markers to better evidence specific co-localizations. 
Irrespective of the cell analyzed, a common feature was 
the relatively low co-localization of HBZ with each one 
of the various markers analyzed. Within this frame, co-
localization between HBZ and CREB-2 in C5MJ (Fig-
ure 6) and ATL-2s (Figure 7) cell lines seemed to be more 
pronounced as compared to the one found in patients 
PH961 tumor cells (Figure 8). A second important feature 
was related to PH961 cells in which all markers showed a 
relatively lower expression compared to the two cell lines, 
probably reflecting the fact the immortalization and 
in  vitro tumor growth induce a generalized overexpres-
sion of genes involved in the homeostasis of cell growth. 
Within the above-mentioned limits, HBZ co-localized 
with CBP and p300 better in C5MJ than in ATL-2s. 
JunD was diffusely expressed in ATL-2s with respect to 
both C5MJ and patient PH961 cells, rendering difficult 
the appreciation of HBZ-JunD co-localization in ATL-2s 
cells. Instead, a detectable co-localization between HBZ 
and JunD was observed in both C5MJ and patient PH961 
cells. HBZ did not co-localize with nucleolin in any of the 
cells under study, indicating that the HTLV-1 viral pro-
tein is not a nucleolar protein.
Discussion
HBZ is an important HTLV-1 viral oncogene that is 
strongly implicated in the neoplastic transformation lead-
ing to ATL [4]. In contrast to Tax-1 oncogene, required 
to initiate neoplastic transformation but not be to main-
tain the oncogenic process, HBZ is constantly found in 
ATL cells [15]. For lack of suitable reagents, however, this 
expression has been assessed mostly at the level of HBZ 
mRNA, and mRNA may not be the best suitable marker 
for HBZ protein expression [30]. In fact, previous reports 
have shown that HBZ protein is scarcely produced in 
the infected cells and is not, or only marginally, dis-
criminated by HBZ specific CTLs [30, 31]. It is therefore 
extremely important to define its modality of expression, 
amount, localization and pattern of interaction with cel-
lular factors during HTLV-1 infection and particularly in 
ATL cells. The above parameters can be defined in vivo 
only by using tools that can detect endogenous HBZ pro-
tein. Among these tools, specific monoclonal antibodies 
are certainly the most appropriate. Indeed, the use of the 
first described anti-HBZ mAb, 4D4-F3, has allowed us to 
better characterize the expression and the localization 
of HBZ molecules in chronically infected HTLV-1 posi-
tive cells as well as in cells from ATL patients, either as 
an established cell line (ATL-2s), or as fresh tumor cells 
from patient PMBC. Moreover, for the first time an esti-
mation of the number of HBZ molecules expressed in 
HTLV-1 infected and ATL tumor cells could be obtained. 
4D4-F3 mAb, raised against the full length spliced HBZ, 
was shown to react specifically with an epitope within the 
97–135 aa region of the protein encompassing the BR1 
region, strongly suggesting that this region is exposed 
on the outer surface of HBZ. The epitope recognized by 
the antibody encompasses a sequence present also in the 
unspliced form of HBZ. Thus, unless the small aminoacid 
difference between spliced and unspliced forms of HBZ 
at the N-terminus of the molecule [11] affects the confor-
mation of the HBZ at distant sites, it would be expected 
that 4D4-F3 mAb recognizes both forms of the HTLV-1 
viral protein.
Figure 5 In vivo interaction of endogenous HBZ with intracellular 
molecules. In vivo interaction between endogenous HBZ and CBP 
or JunD was assessed by co-immunoprecipitation assay. Cell lysates 
from 50 million C5MJ, ATL-2s, PH961 ATL patient and Jurkat cells, 
prepared as described in the legend to Figure 2, were immunopre-
cipitated by using HBZ covalently linked to CNBr-activated Sepharose 
4B beads (IP αHBZ). After elution from HBZ-Sepharose 4B beads, the 
eluted material was migrated on SDS-PAGE gels, blotted on nitrocel-
lulose membranes and probed with antibodies specific for either 
anti-HBZ (4D4-F3 mAb, αHBZ WB), anti-CBP (αCBP WB) or anti-JunD 
(αJunD WB) (lower western blots in each series of upper, middle and 
lower panels, respectively). One twentieth of cell lysate from each 
sample was used to assess the presence of the specific protein (input) 
by western blot (upper western blot in each series of upper, middle 
and lower panels).
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Figure 6 Co-localization of endogenous HBZ with intracellular factors in C5MJ cells. C5MJ cells were reacted in a pairwise combination with the 
4D4-F3 anti HBZ mAb antibody, and either polyclonal rabbit anti-CBP, anti-JunD, anti-p300, anti-CREB2, or anti-nucleolin antibodies. Anti-HBZ mAb 
was revealed by Alexa fluor 546-labeled goat anti-mouse IgG (red), whereas the other rabbit antibodies were revealed by Alexa fluor 488-labeled 
goat anti-rabbit antibodies (green). The MERGE column panels represent the merge between the Alexa fluor 546 and the Alexa fluor 488 signals. A 
co-localization of HBZ with either one of the intracellular factors results in a yellow color. The reference of intensity (ROI) drawn along mid-nucleus 
level of the merge image (insert) is represented by red and green peaks in the histogram (red for HBZ and green for the intracellular factor).
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Figure 7 Co-localization of endogenous HBZ with intracellular factors in ATL-2s cells. ATL-2s cells were reacted in a pairwise combination with the 
4D4-F3 anti HBZ mAb antibody, and either polyclonal rabbit anti-CBP, anti-JunD, anti-p300, anti-CREB2, or anti-nucleolin. For detection and other 
relevant informations see the legend to Figure 6.
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Figure 8 Co-localization of endogenous HBZ with intracellular factors in PH961 cells. PH961 patient cells were reacted in a pairwise combination 
with the 4D4-F3 anti HBZ mAb antibody, and either polyclonal rabbit anti-CBP, anti-JunD, anti-p300, anti-CREB2, or anti-nucleolin. For detection and 
other relevant information see the legend to Figure 6.
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Naturally expressed HBZ protein localized in the 
nucleus with a similar speckle-like distribution as the 
one observed in cells transfected with tagged HBZ pro-
tein. However several previously described aggregates of 
nuclear HBZ were shown to be artifacts of chimeric pro-
teins, particularly in studies conducted with GFP-HBZ 
constructs. Moreover, HBZ-specific nuclear speckles did 
not overlap with similar speckle-like structures such as 
PML-NB involved in the co-activation of HTLV-1 Tax 
oncoprotein [29], indicating that HBZ does not co-local-
ize with PML protein.
These findings emphasize the usefulness of our anti-
HBZ mAb to better delineate the intracellular pattern 
of expression of HBZ. Confocal microscopy analysis 
of C5MJ, ATL-2s and particularly PBMC of the PH961 
ATL patient indicated that the vast majority of the cells 
expressed HBZ. The percentage of positive cells varied 
from 75% in C5MJ, to 80% in PH961 ATL patient cells, 
and virtually 100% in ATL-2s cells. The results obtained 
in fresh PBMC of the PH961 ATL patient having a leuke-
mic hyperlymphocytosis (400.000 cells/mm3) are impor-
tant because they indicate that not only the vast majority 
of the PBMC are ATL tumor cells but also that virtually 
all of them express HBZ protein. PH961 patient ATL cells 
displayed a cell surface phenotype with 100% of the cells 
co-expressing CD3 and CD25 molecules, compatible 
with a T cell-activated phenotype, although these cells 
were only 26% positive for CD4 and negative for CD8 cell 
surface molecules. Thus most of the leukemic cells did 
not present the phenotypic characteristics of regulatory 
T cells (Tregs, CD4+/CD25+) or effector/memory T 
cells that are supposed to be the major targets of HTLV-
1-mediated cellular transformation [24, 25, 32]. More 
refined studies are presently underway to further clarify 
the phenotype and the possible functional correlates of 
CD3+/CD25+/CD4− and CD3+/CD25+/CD4+ cells in 
PH961 patient. It must be stressed, however, that also the 
cell surface phenotype of the ATL-2s cell line was rather 
peculiar, as ATL-2s cells expressed very low amount, if 
any, of CD3 and CD4 molecules and only very limited 
amount of CD25 molecules (Additional file 2: Figure S2).
The availability of 4D4-F3 mAb has allowed for the 
first time to make an estimate of the number of HBZ 
molecules expressed on a per-cell basis in chronically 
infected C5MJ and in ATL tumor cells. In the three cells 
this number was far less (20- to 50-fold less) than the one 
expressed in HBZ-transfected cells such as Cos cells or 
293T cells, used by most investigators to characterize the 
pattern of expression, the co-localization and the possible 
interaction of HBZ with cellular factors. In absolute num-
ber C5MJ, ATL-2s and patient PH961 cells contained 
33.385, 39.615 and 17.461 molecules per cell, respec-
tively, compared to an average of 783.000 molecules 
observed in HBZ-transfected 293T cells. These results 
may help to better understand and evaluate the quan-
titative expression of HBZ during the various phases of 
HTLV-1 infection leading to chronic infection and even-
tually to neoplastic transformation. Future investigation 
will be focused on these important aspects.
Many nuclear factors have been reported to inter-
act with HBZ. However most of these interactions were 
assessed in 293T or COS cells transfected with tagged 
HBZ, thus in HBZ overexpression conditions and in non-
physiological cellular models of HBZ expression. In this 
study we demonstrated that endogenous HBZ expressed 
in chronically infected and in ATL tumor cells inter-
act in  vivo with cellular transcription factors that are 
involved both in the control of HTLV-1 replication and 
in the host cell homeostasis. We could show that native 
HBZ can interact with CBP and JunD both in C5MJ and 
in the ATL tumor cells, although to different extent. In 
the two cell lines C5MJ and ATL-2s the interaction was 
consistently higher than the one observed in fresh ATL 
patient PH961 cells and partially correlated to the higher 
expression of HBZ protein in the former cell lines com-
pared to the latter fresh tumor cells. These results conclu-
sively demonstrate that native HBZ can indeed interact 
in  vivo with CBP and JunD in  situations of “physiologi-
cal” expression of the viral protein both in chronically 
HTLV-1 infected cells and in ATL tumor cells. This study 
did not address the question of whether these interac-
tions, as well as other described interactions such as the 
HBZ-CREB-2 and HBZ-p300, have a crucial functional 
role on the homeostasis of HTLV-1-infected cells and a 
causative implication in the cellular transformation lead-
ing to the ATL phenotype. Nevertheless, in C5MJ, ATL-
2s and patient PH961 cells careful confocal microscopy 
analysis of co-localization of HBZ with either CBP, JunD, 
p300 or CREB-2 clearly demonstrated a partial, often 
only minor co-localization between the viral protein and 
the cellular nuclear factors. Thus, possible functional cor-
relates of each single interaction of HBZ with the above 
nuclear factors in HTLV-1 infected and ATL cells should 
be framed within these findings.
Conclusions
In conclusion, we believe that the availability of the 4D4-
F3 anti-HBZ mAb may significantly contribute to a bet-
ter delineation of the role and presence of HBZ during 
HTLV-1 infection and cellular transformation.
Methods
HBZ constructs
The HBZ plasmid pGEX2T-HBZ, used to prepare the 
recombinant GST-HBZ protein in its spliced form used 
for immunization (see below), was a gift of Dr. Lemasson, 
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University East Carolina, USA [16]. Plasmid encod-
ing myc-tagged HBZ, comprising also an histidine tag 
after the short myc sequence, was a gift of Dr. Matsuoka, 
Univ. of Kyoto, Japan. After expression, this recombinant 
protein has an apparent molecular weight of 36 kDa [8]. 
Full length and mutant fragments of GFP-tagged HBZ 
(pEGFPc2.HBZ plasmids) were provided by Dr. Mesnard, 
Montpellier, France [33]. Plasmid encoding untagged HBZ 
(pcDNA3.HBZ) was obtained by double digestion of the 
pEGFPc2.HBZ full length plasmid with XbaI and HindIII 
and ligation of the resulting HBZ sequence to correspond-
ing restriction sites of the plasmid pcDNA3.1hygro (+).
Recombinant HBZ protein production, purification 
and quantification
pGEX2T-HBZ plasmid was used to transform rosetta 
bacterial cells (rosetta-gami pLysS competent cells, 
Novagen, Merck Millipore, Germany). The cells were 
grown with ampicillin and chloramphenicol selection 
as suggested by the manufacturer. When the absorb-
ance at 600  nm reached 1.0, 1  mM isopropyl beta-D-
1-thiogalactopyranoside (IPTG) was added to induce 
the recombinant protein expression. After overnight 
incubation at 37°C, the culture was centrifuged to get 
the pellet. In order to lyse the bacterial cells we used a 
modified RIPA buffer (Tris–HCl 20  mM pH 8.5; NaCl 
500 mM; EDTA 1 mM; Tween 20 0.2%; Protease inhibi-
tor mix from Roche, Milan, Italy). The lysate was soni-
cated at 50% power, 30 s (0.9/0.1 pulse) for three times. 
The lysate was then centrifuged at 4,500 rpm for 30 min 
to get the supernatant and pellet. To purify the recom-
binant protein (HBZ-GST), agarose glutathione beads 
(Thermo Scientific, Rockford, USA) were mixed with 
the lysate obtained above and incubated overnight on a 
rotor wheel at 4°C. Next day, the beads were washed and 
the recombinant protein was eluted with elution buffer 
(Tris 50  mM, Nacl 150  mM pH 8, reduced glutathione 
10 mM). All washes and eluants were stored at −20°C for 
further analysis. In order to quantify the fusion protein, a 
protein assay kit (BCA, Thermo Scientific) was used fol-
lowing manufacturer’s instructions.
Cells
COS and 293T cell lines were cultured in DMEM 
medium, supplemented with 10% fetal calf serum (FCS) 
and glutamine. HTLV-1 chronically infected cell line 
C5MJ [34] was kindly obtained from Dr. Macchi, Uni-
versity of Rome Tor Vergata and maintained in RPMI-
FCS 10%. The ATL tumor cell line ATL-2s was obtained 
from Dr. Matsuoka, Japan [35]. Peripheral blood monu-
clear cells (PBMC) PH961 were from a patient under the 
epidemiological control of the Pasteur Institute, Paris, 
France, with a typical acute ATL form characterized by a 
high level of circulating leukemic cells, very high hyper-
lymphocytosis with lymphocyte count of 400 000  lym-
phocytes/mm3. HTLV-1 infection was confirmed by 
Western blot on plasma sample and anti-HTLV-1 anti-
bodies in patient’ plasma were titrated through indirect 
immunofluorescence using the HTLV-1-producing MT-2 
cell line, as described previously [36]. Anti-HTLV-1 anti-
body titer of patient from patient PH961 was 1/10,240. 
Patient’s data were analyzed anonymously.
The immunophenotype of C5MJ, ATL-2s and patient 
PH961 PBMC was assessed by immunofluorescence and 
flow cytometry (BD FACSAria II™ apparatus) using the 
following monoclonal antibodies: mouse anti-human 
HLA class I (clone B9.12); mouse anti-human HLA class II 
DR (clone D1.12); mouse anti-human CD19 (clone HIB19, 
BD Pharmingen); mouse anti-human CD16 (clone 3G8, 
BD Pharmingen, Milan, Italy); the above antibodies were 
revealed by FITC-labelled rabbit anti-mouse IgG F(ab’)2 
antiserum (Sigma, Milan, Italy); FITC mouse anti-human 
CD3 (clone (UCHT1 BD Pharmingen); FITC mouse anti-
human CD4 (clone RPA-T4, BD Pharmingen); phyco-
erythrin (PE) mouse anti-human CD25 (clone M-A251, 
BD Pharmingen), and PE-Cy5 mouse anti-human CD8a 
(clone RPA-T8; eBioscience, Milan, Italy). Incubation and 
staining procedures were as previously described [37].
Mice immunization and generation of anti‑HBZ 
monoclonal antibody
All animal work has been conducted according to relevant 
national and international guidelines and was approved 
by the University of Insubria Internal Ethical Commit-
tee CESA (project 07-2013) and by the Italian Minis-
try of Health. Six-week-old female BALB/c mice were 
injected intraperitoneal on day 1 and day 20 with 10 µg of 
HBZ-GST protein in Complete Freund’s Adjuvant, total 
injected volume of 250 µl (125 µl PBS and 125 µl of Com-
plete Freund’s Adjuvant). On days 43 and 68, HBZ-GST 
protein injections were repeated by using Incomplete Fre-
und’s Adjuvant. Mouse serum was checked for anti-HBZ 
positivity on day 72 before sacrificing the animal. Total 
splenocytes were fused with 10 million P3U1 myeloma 
cells in presence of PEG as described [38]. The hybrido-
mas were grown in selecting RPMI-HAT (Hypoxanthine 
Aminopterin Thymidine) medium. Initial screening of 
hybridoma supernatants was performed by an indirect 
enzyme-linked immunoadsorbent assay (protein detec-
tor ELISA kit, KPL). Briefly, 100 μl of purified GST-HBZ 
protein solution (1 μg/ml in PBS) was adsorbed onto the 
plate wells for 1  h at RT. Protein solution was removed 
and wells were saturated with 1× blocking solution for 
1  h at RT. Hundred microliters of hybridoma superna-
tants were then added to the wells and incubated for 1 h 
at RT. After washing, peroxidase-labeled goat anti-mouse 
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IgG was added and incubated for 1  h at RT. Finally, the 
substrate and stop solution were added and the plate was 
read at 405 nm in a spectrophotometer. The mouse serum 
from immunized animals was used as a positive control 
and the supernatant of P3U1 myeloma cells or normal 
mouse serum served as a negative control.
Hybridoma supernatants were also screened for anti-
HBZ positivity by western blot. To this purpose cell 
lysates from Cos cells transfected with myc-HBZ (see 
below) was run on a 10% SDS-PAGE gel and transferred 
onto nitrocellulose membrane (Amersham high bond 
ECL, GE, Buckinghamshire, UK). The membrane was 
then quenched in 5% non-fat milk in 1× TBS containing 
0.05% Tween-20 (MTTBS) for 1 h at room temperature. 
Hybridoma supernatant, diluted 1:1 with 5% MTTBS was 
then added and membrane incubated overnight at 4°C. 
After appropriate washes with MTTBS, HRP conjugated 
goat anti-mouse IgG was used as secondary antibody for 
1  h at room temperature. The membranes were devel-
oped using the ECL system (Pierce, Rockford, USA) and 
exposed to X-ray film.
To determine the antibody isotype, we used Pierce 
rapid ELISA mouse mAb isotyping kit. Appropri-
ately diluted hybridoma supernatant was added to 
the wells pre-coated with anti-mouse heavy or anti-
mouse light chain capture antibody. Goat anti-mouse 
IgG + IgM + IgA HRP conjugate was then added to the 
wells and incubated for 1 h at room temperature. Follow-
ing washes, TMB substrate and stop solution were added 
following manufacturer’ instructions and spectrofluoro-
metric measure performed at 450 nm.
Transfection procedures
Cos cells or 293T cells were transfected with full length 
HBZ constructs (GFP-HBZ, myc-HBZ, or untagged HBZ) 
or GFP-tagged HBZ fragments (∆ZIP, ∆AD, BR1, DBD, 
BR1-BR2-DBD) as previously described [39]. Briefly, 
3 × 106 COS or 293T cells were seeded in 35-mm-diam-
eter plates and transfected with 3  μg of plasmid DNA 
constructs using Lipofectamine (Invitrogen, Milan, Italy). 
Cell extracts were prepared 24  h post-transfection and 
analyzed for the expression of recombinant proteins by 
SDS-PAGE and Western blotting with the anti-Myc 9E10 
antibody (Santa Cruz Biotechnology) to detect myc-
tagged HBZ. Horseradish peroxidase (HRP)-conjugated 
anti-mouse immunoglobulin secondary antibody (Amer-
sham, Milan, Italy) was used. Blots were developed by 
chemiluminescence assay (Immune-Star HRP substrate; 
Bio-Rad, Milan, Italy).
Confocal microscopy
Appropriate number of cells were plated onto a steri-
lized cover slip (pre-coated with D-polylysine 0.1 μg/ml, 
Sigma, Milan, Italy) placed in a six-well plate. After 24 h, 
transfection with 3 μg plasmid coding for HBZ-Myc or 
HBZ-GFP or different HBZ mutants was performed as 
above. The cells were then washed with PBS 1× three 
times and fixed with methanol (−20°C) for 4–6 min. Cells 
were washed three times with PBS, and incubated with a 
solution of 0.5% BSA in PBS for 1 h. The anti-HBZ mAb 
was then added as primary antibody and incubated over-
night at 4°C. Alexa fluor 546 IgG1 goat anti-mouse was 
used as secondary antibody for detecting the monoclo-
nal antibody. After three washes with PBS, the cover slip 
was mounted onto a glass slide using a drop of mounting 
medium and sealed. The images were visualized by a Lei-
caTCS SP5 confocal microscope (objective lenses: HCX 
PL APO, 63× original magnification, numerical aper-
ture: 1.25) and imported into LAS AF software. A similar 
protocol was used for HTLV-1 infected cells C5MJ and 
ATL-2s. To assess co-localization of HBZ with host cellu-
lar factors C5MJ, ATL-2s and PH961 cells were reacted in 
a pairwise combination with the 4D4-F3 anti HBZ mAb 
antibody, and either polyclonal rabbit anti-PML, anti-
CBP, anti-JunD, anti-p300, anti-CREB2, or anti-nucleolin, 
all from Santa Cruz Biotechnology, Ca, USA. Anti-HBZ 
mAb was revealed by Alexa fluor 546-labeled goat anti-
mouse IgG (red), whereas the other rabbit antibodies 
were revealed by Alexa fluor 488-labeled goat anti-rabbit 
antibodies (green).
Quantitative assessment of HBZ in chronically infected 
and in ATL tumor cell lines
Endogenous HBZ expression was quantitated by using 
the anti-HBZ monoclonal antibody 4D4-F3. To this pur-
pose increasing amounts of purified GST-HBZ protein 
were migrated in SDS-PAGE, blotted with the 4D4-F3 
antibody, and the intensity of resulting bands analyzed by 
densitometry to construct a standard curve. Cell lysates 
from endogenously HBZ-producing cells or HBZ-trans-
fected cells were then assayed for the presence of HBZ 
by western blot; the intensity of the resulting bands was 
measured by densitometry as above and plotted on the 
densitometry standard curve obtained with purified 
GST-HBZ. Densitometry measurements and elabora-
tion of data were carried out using the ImageJ software 
(Image Processing and Analysis in Java, http://imagej.
nih.gov/ij/) The deduced concentration of HBZ in cells 
was obtained by taking into account the total number of 
cells used for preparing the cell lysate, the volume of cell 
lysate used and the percentage of positive cells visual-
ized by confocal microscopy in parallel experiments. The 
obtained number in amount/cell was then converted in 
number of moles/cell taking into account the molecu-
lar weight of endogenous HBZ by the formula: [HBZgr/
HBZmw  =  HBZmoles]. Mole value (HBZmoles) was then 
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transformed in number of molecules/cell by multiply-
ing it for the Avogadro number following the formula: 
Nmolecules = 6 × 1023 × HBZmoles.
Co‑immunoprecipitation
Lysates of ATL-2s, C5 MJ, PH961 cells, as well as lysate 
of HBZ-transfected 293T cells, or lysate from human 
T cell line Jurkat used as negative control, were pre-
pared by using a non-denaturing lysis buffer (NP-40 1%, 
Tris-base 10  mM pH 7.4, Nacl 150  mM, EDTA 2  mM). 
Albumin-coupled Sepharose 4B beads (20  μl packed 
beads) were washed with the same lysis buffer and used 
to pre-clearing the lysates for 1  h at 4°C. For co-immu-
noprecipitation, the 4D4-F3 antibody was covalently 
linked to CNBr-activated Sepharose 4B beads following 
standard procedures. For this purpose 10  mg of puri-
fied 4D4-F3 mAb was covalently linked to 1 g dry weight 
Sepharose 4B as described [40]. Lysates were then incu-
bated with 4D4-F3-coupled Sepharose 4B beads (10  μl 
packed beads/10  ×  106  cell equivalent) overnight at 
4°C. 4D4-F3-coupled Sepharose 4B beads were washed 
six times with lysis buffer. Finally the beads were resus-
pended in 50 μl of loading buffer 2×, boiled and run on 
SDS-PAGE gel. After gel blotting on membranes, mem-
branes were incubated with appropriate primary and sec-
ondary antibodies, exposed and developed as described 
above.
Additional files
Additional file 1: Figure S1. Specificity of the 4D4 parental and its 
cloned 4D4-F3 hybridoma for HBZ molecule. Cell lysates of Cos cells trans-
fected with myc-tagged HBZ (HBZmyc) or non transfectd (mock) were 
migrated on SDS-PAGE gels, blotted on nitrocellulose membranes and 
probed with supernatant from the 4D4 parental hybridoma or its cloned 
product 4D4-F3, raised against a GST-tagged HBZ protein. As negative 
control, the supernatant of the P3U1 myeloma cells used for somatic cell 
fusion was used.
Additional file 2: Figure S2. Cell surface phenotype of C5MJ, ATL-2s 
and patient PH961 cells. Cell surface phenotype of C5MJ, ATL-2s cell lines 
and of peripheral blood mononuclear cells from ATL patient PH961 was 
assessed by immunofluorescence and flow cytometry. The various cell 
surface markers listed in the top right of each histogram were assessed 
by specific monoclonal antibodies either unlabeled (HLA class I and HLA 
class II DR) followed by incubation with FITC-labeled rabbit anti-mouse 
IgG, or directly labeled with fluorochromes (CD3, CD4, CD8, CD25, CD19, 
and CD16). Specific fluorescence is represented by the bold histogram; 
negative isotype control is represented by the thin histogram. Values are 
expressed in the abscissa as mean fluorescence in arbitrary units (au).
Additional file 3 Figure S3. HBZ nuclear speckles do not co-localize 
with PML nuclear bodies (PML-NB). ATL-2s cells were reacted in a pairwise 
combination with the 4D4-F3 ant-HBZ mAb antibody and a polyclonal 
rabbit anti-PML antiserum. Anti-HBZ mAb was revealed by Alexa fluor 546 
labeled goat anti-mouse IgG (red), whereas the rabbit antibodies were 
revealed by Alexa fluor 488-labeled goat anti-rabbit antibodies (green). 
Two representative cells are shown. The “merge” column panels represent 
the merge between the Alexa fluor 546 and the Alexa fluor 488 signals. A 
co-localization of HBZ with PML would result in a yellow color. Differential 
interference contrast (DIC) image of each cell analyzed is shown in the last 
column panels.
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